Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II single center study to administer two courses of myeloablative
consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC)
rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy
(independent of this study). Ideally, patients should begin consolidation chemotherapy no
later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended
to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.